DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin

Information source: Kadmon Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatitis C

Intervention: Infergen and ribavirin (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Kadmon Pharmaceuticals

Official(s) and/or principal investigator(s):
Mitchell L Schiffman, MD, Principal Investigator, Affiliation: Virginia Commonwealth University

Summary

This is a 60-to-72 week multicenter study to evaluate Infergen and Ribavirin in patients with Chronic Hepatitis C Virus after partial response to treatment using peginterferon-alfa and Ribavirin therapy. The study will be conducted at approximately 50 sites across the United States.

Clinical Details

Official title: Phase 4 Study Using Infergen and Ribavirin in Patients With Chronic Hepatitis C Virus Who Achieved Partial Response to Peginterferon-alfa and Ribavirin Therapy

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To evaluate the proportion of patients with a sustained viral response (SVR) defined as undetectable serum HCV RNA at the end of the 24 week post-treatment follow-up period.

Secondary outcome: Compare proportion of patients with SVR after switching treatment with Infergen/Ribavirin for 48 weeks versus those treated for 36 weeks

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female, at least 18 years of age and no older than 65 years with compensated

chronic HCV infection based on a history of positive serum anti-HCV antibody and/or HCV RNA

- Diagnosed with HCV Genotype 1, 4, 5 or 6 as determined during the screening visit

- The starting doses in the initial treatment must have been 1. 5 μg/kg/week PEG-Intron

or 180 μg/week Pegasys, and 1000/1200 mg/day ribavirin based on body weight. Patients must have been at least 80% compliant during the initial peginterferon/ribavirin therapy, per patient account.

- Liver biopsy indicating F0-F4 must be performed within 3 years prior to screening.

Documentation of the results of the biopsy must be available. If documentation is not available, a liver biopsy must be performed during the screening period. (A maximum of 10 patients in each of the three treatment groups will be patients with a fibrosis score of F4)

- Documented partial response after 12 weeks of treatment as a therapy-naive patient

with one course of peginterferon alfa-2a (PEGASYS) and Ribavirin or peginterferon alfa-2b (Peg-INTRON) and Ribavirin Exclusion Criteria:

- Detectable HCV RNA after 12 weeks if initial peginterferon alfa/ribavirin therapy and

<2 log decrease in HCV RNA at Week 12 from baseline.

- HCV Genotype 2 or 3

- Severe neuropsychiatric disorder.

- History or clinical manifestations of significant metabolic, hematological,

pulmonary, ischemic heart disease, significant or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic disorders including severe retinopathy, or immune-mediated disease.

- Known HIV infection or positive HIV at screening.

- Pregnant or breast-feeding patients.

- Underlying autoimmune disease

Locations and Contacts

Atlantic Gastroenterology Associates, Atlanta, Georgia, United States

Tulane University School of Medicine, New Orleans, Louisiana, United States

Caroline Digestive Health Associates, Harrisburg, North Carolina, United States

Liver Institute at Methodist Dallas, Dallas, Texas, United States

Additional Information

Starting date: February 2007
Last updated: October 11, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017